The Vasoactive Intestinal Peptide Receptor Axis in Translational Medicine: Therapeutic Opportunities and Biomarker Potential
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 15 January 2027 | Viewed by 99
Editors
2. Departmental Section of Cell Biology and Histology, Faculty of Medicine, Complutense University of Madrid (ROR 02p0gd045), Madrid, Spain
Interests: vasoactive intestinal peptide; VPAC receptors; biomarkers; inflammation; autoimmunity; rheumatic diseases; translational medicine
2. Department of Cell Biology and Histology, Faculty of Biological Science, Complutense University of Madrid (ROR 02p0gd045), Madrid, Spain
Interests: vasoactive intestinal peptide; VPAC receptors; lymphocytes; biomarkers; inflammation; autoimmunity; rheumatic diseases; bone metabolism; translational medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Vasoactive intestinal peptide (VIP) is a pleiotropic peptide involved in neuroendocrine–immune communication, inflammation, immune tolerance, tissue homeostasis and repair. Through its receptors, mainly VPAC1 and VPAC2, VIP regulates key cellular and molecular pathways that have attracted growing interest for the development of novel therapeutic approaches. Recent advances in optimized VIP analogues, receptor-targeted strategies, innovative delivery systems and biomarker-guided approaches are opening new opportunities to improve clinical applicability. The VIP/VPAC receptor axis has shown potential relevance in a broad range of pathological settings, including autoimmune and inflammatory diseases, respiratory disorders, neurological diseases, metabolic and cardiovascular conditions, and cancer. This Special Issue aims to provide an updated and multidisciplinary view of the therapeutic potential of VIP, VIP analogues and VIP receptor-targeted strategies. Original research articles and reviews addressing disease mechanisms, receptor signaling, receptor-selective ligands, pharmacological optimization, innovative delivery systems, and preclinical or clinical applications are welcome. Contributions exploring VIP and its receptors as biomarkers, as well as their role in patient stratification and precision medicine, are also encouraged. We look forward to receiving your valuable contributions and hope this Special Issue will highlight current advances, remaining challenges and future opportunities for translating the VIP/VPAC receptor axis into clinical practice.
Prof. Dr. Carmen Martínez
Dr. Yasmina Juarranz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vasoactive intestinal peptide
- VPAC1 receptor
- VPAC2 receptor
- peptide therapeutics
- receptor-targeted strategies
- drug delivery systems
- biomarkers
- inflammation
- immunomodulation
- translational medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
